Based on years of research and trials at major medical institutions, Rebion is commercializing the breakthrough Neural Performance Scanning (NPS) to precisely measure signal patterns that return from the brain, instantly determining if faulty signal processing is present. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible.
What is NPS?
Using proprietary retinal scanning to quantify bilateral fixation and saccadic movement, NPS measures the neurophysiologic mechanism of the optic nerve/brain continuum, instantly identifying impairments.
Direct Detection, instead of screening for just risk factors, of Micro-Strabismus and Amblyopia is Now Possible! Based on years of R&D into new technologies at major medical institutions, Rebion now offers Blinq®, the only FDA cleared portable neural performance scanner, that actually detects micro-strabismus and amblyopia (lazy eye). Blinq conducts a 3-second Neural Performance Scan of the fovea to accurately detect binocularity associated with as little as 1-degree misalignment.
Leveraging NPS to measure visual tracking impairments Rebion’s Traq.™ device uses Neural Performance Scanning (NPS) to support clinical research focused on visual tracking, with the goal of translating these insights into future clinical tools. Traq is currently investigational and not available for sale in the United States
Who We Serve
Blinq’s Evidence & Impact
Backed by peer-reviewed clinical studies and years of research at leading medical institutions, Blinq delivers proven, real-world accuracy in early vision screening. Unlike traditional tools that estimate risk, Blinq directly detects amblyopia and strabismus—achieving up to 100% sensitivity and over 90% specificity in clinical evaluations—while reducing unnecessary referrals and missed diagnoses. This evidence-driven approach enables earlier intervention, improves patient outcomes, and supports more effective, scalable screening programs across clinics, schools, and public health initiatives.
-
Mark Maire has been tapped to lead Rebion into the future
-
NIH-funded study shows screening device accurately detects amblyopia (lazy eye)
-
Newly Published Clinical Trial Shows Unprecedented Accuracy of Rebion's Blinq® Vision Scanner in Pediatric Vision Screening